Clinical Trial ResultsIn Phase 1, rosnilimab showed a 90% reduction of T cell proliferation, inflammatory cytokine secretion and PD-1(high) T cells and demonstrated favorable safety.
Market PotentialRosnilimab could be a best-in-class PD-1 agonist, in analysts' view.
Product DifferentiationANB032 offers a differentiated pathway, targeting a broad spectrum of immune cells that have been implicated in AD progression including Th1/Th2/Th17/Th22 and potentially DCs.